A prospective, randomised, double-blind, placebo-controlled, parallel group dose ranging study in asthma patients in Iceland to assess the safety, tolerability and efficacy of the MLK inhibitor, CEP-1347
Phase of Trial: Phase II
Latest Information Update: 23 May 2011
At a glance
- Drugs CEP 1347 (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors deCODE genetics
- 07 Jun 2017 Biomarkers information updated
- 23 May 2011 Last checked against European Clinical Trials record.
- 05 Nov 2010 New trial record.